Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,601 to 1,620 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrated bioinformatic analysis identified a novel prognostic pan-programmed cell death signature for bladder cancer. | Front Immunol | 2022 | 36505448 | PubTator, text mining | PubMed |
| Targeting FTO Suppresses Pancreatic Carcinogenesis via Regulating Stem Cell Maintenance and EMT Pathway. | Cancers (Basel) | 2022 | 36497402 | PubTator, text mining | PubMed |
| Genomewide m6A Mapping Uncovers Dynamic Changes in the m6A Epitranscriptome of Cisplatin-Treated Apoptotic HeLa Cells. | Cells | 2022 | 36497162 | PubTator, text mining | PubMed |
| N6-methyladenosine regulators-related immune genes enable predict graft loss and discriminate T-cell mediate rejection in kidney transplantation biopsies for cause. | Front Immunol | 2022 | 36483557 | PubTator, text mining | PubMed |
| Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research. | Front Oncol | 2022 | 36483051 | PubTator, text mining | PubMed |
| Novel insight of N6-methyladenosine modified subtypes in abdominal aortic aneurysm. | Front Genet | 2022 | 36482903 | PubTator, text mining | PubMed |
| SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma. | Discov Oncol | 2022 | 36477668 | PubTator, text mining | PubMed |
| METTL3 promotes glycolysis and cholangiocarcinoma progression by mediating the m6A modification of AKR1B10. | Cancer Cell Int | 2022 | 36476503 | PubTator, text mining | PubMed |
| Exosomal miR-628-5p from M1 polarized macrophages hinders m6A modification of circFUT8 to suppress hepatocellular carcinoma progression. | Cell Mol Biol Lett | 2022 | 36474147 | PubTator, text mining | PubMed |
| LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC. | J Exp Clin Cancer Res | 2022 | 36471363 | PubTator, text mining | PubMed |
| Identification of RNA N6-methyladenosine regulation in epilepsy: Significance of the cell death mode, glycometabolism, and drug reactivity. | Front Genet | 2022 | 36468034 | PubTator, text mining | PubMed |
| Non-coding RNA and n6-methyladenosine modification play crucial roles in neuropathic pain. | Front Mol Neurosci | 2022 | 36466810 | PubTator, text mining | PubMed |
| The emerging roles of N6-methyladenosine in osteoarthritis. | Front Mol Neurosci | 2022 | 36466802 | PubTator, text mining | PubMed |
| The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome. | Front Med (Lausanne) | 2022 | 36465909 | PubTator, text mining | PubMed |
| The impact of the microbiome in cancer: Targeting metabolism of cancer cells and host. | Front Oncol | 2022 | 36465375 | PubTator, text mining | PubMed |
| TWIK-related acid-sensitive K+ channel 2 promotes renal fibrosis by inducing cell-cycle arrest. | iScience | 2022 | 36465115 | PubTator, text mining | PubMed |
| The risk of COVID-19 can be predicted by a nomogram based on m6A-related genes. | Infect Genet Evol | 2022 | 36460278 | PubTator, text mining | PubMed |
| The m6A methylation profiles of immune cells in type 1 diabetes mellitus. | Front Immunol | 2022 | 36457997 | PubTator, text mining | PubMed |
| IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells. | Mater Today Bio | 2022 | 36457846 | PubTator, text mining | PubMed |
| N6-Methyladenosine Regulator-Mediated RNA Methylation Is Involved in Primary Sjögren's Syndrome Immunoinfiltration. | Dis Markers | 2022 | 36457545 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=81